Kolosis BIO Attends 2024 AAOS Annual Meeting
The Kolosis team will be attending the upcoming American Academy of Orthopedic Surgeons (AAOS) 2024 Annual Meeting in San Francisco, California. This yearly conference consists of numerous events and sessions centered around education, innovation, and collaboration within the global orthopedic community. The Kolosis team will be available throughout the week for meetings to discuss our […]
Kolosis BIO Announces Strong 2023 Results
Kolosis bone grafts continue gaining substantial market presence, now available in over 450 hospitals and surgical facilities across 48 states Kore Fiber and Prime HD grafts utilized in over 16,000 fusion procedures in 2023, a 33% increase from the previous year. Kolosis BIO channel partners now topping more than 200 independent distributors in the spine […]
Kolosis BIO Exhibits at 65th Annual SOMOS Meeting
Kolosis BIO (Kolosis) is honored to exhibit at the 65th Annual Meeting of the Society of Military Orthopedic Surgeons (SOMOS) in Vail, Colorado. The Kolosis team hosted a booth where surgeons and professionals explored our advanced technologies designed to optimize bone fusions and aid in the healing process of complex surgical wounds. The SOMOS Annual […]
Kolosis BIO Attends 2023 NASS Conference
The Kolosis team will be attending the 2023 North American Spine Society (NASS) Conference in Los Angeles, California. The NASS conference features the latest spine education including surgical, medical, and interdisciplinary sessions. This annual event connects top professionals and experts in the field. Kolosis will have the opportunity to dive into the latest research and […]
Kolosis BIO Recognized as Utah Fast 50 Emerging Company
Kolosis BIO (Kolosis) is proud to announce their recognition as a Utah Fast 50 Emerging Company. Every year, Utah Business awards the fastest growing companies in the state and recognizes emerging companies. Kolosis, a leading provider of innovative biologics, was among the companies recognized by Utah Business for distinguishing themselves as a strong competitor in […]
Kolosis BIO and MTF Biologics Forge Strategic Partnership to Enter Surgical Incision Market
Kolosis BIO (Kolosis), a leading provider of biologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are excited to announce their partnership in the surgical incision market.
Kolosis BIO and MTF Biologics Extend Exclusive Agreement
Kolosis BIO (Kolosis), a leading provider of orthobiologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are proud to announce the extension of their successful partnership.
Kolosis BIO Announces Strong 2022 Results
Kolosis BIO, LLC (Kolosis), a pure-play biologics company and an exclusive bone graft partner to MTF Biologics, announced today its 2022 results and 2023 expectations.
Kolosis BIO Announces the Appointment of Charles Crockett as Area Vice President, East
Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Charles Crockett as Area Vice President of Sales, East.
Kolosis BIO Announces the Appointment of Michelle Soleimani-Mafi as Director of Operations
Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Michelle Soleimani-Mafi as its Director of Operations.